
Sign up to save your podcasts
Or


In this week's episode we’ll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias.
Featured Articles:
By American Society of Hematology4.1
4949 ratings
In this week's episode we’ll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias.
Featured Articles:

11,147 Listeners

140 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,157 Listeners

2 Listeners

363 Listeners

373 Listeners

1 Listeners

48 Listeners

190 Listeners

30 Listeners

4 Listeners